Rubicon Research Ltd Share Price Today

Rubicon Research Ltd. Share Price

Overview

Rubicon Research Ltd. share price is currently ₹1,790.45, down by - ₹37.75 (2.06%) from its previous closing price of ₹1,828.20. The share price has gained 8.96% over the past month and declined -2.53% over the past year. The stock's 52-week low and high are ₹570.75 and ₹1,876.44, respectively. Rubicon Research Ltd. has a market capitalisation of ₹ 29,270.00 Cr. The share price was last updated on 09 Sep 2026, 03:57 PM IST.

Actions	Ex-Date	Record-Date
DividendsFinal Dividend of 150% at ₹1.5/Share	07-Aug-2026	07-Aug-2026

Actions

Ex-Date

Record-Date

DividendsFinal Dividend of 150% at ₹1.5/Share

07-Aug-2026

Mutual Fund Holder	Jun 26 Shares held	Jul 26 Shares held
Kotak Midcap Fund - Regular Plan - Growth	37.78 Lac	37.78 Lac no change
Motilal Oswal Small Cap Fund - Regular Plan - Growth	22.58 Lac	22.58 Lac no change
Bajaj Finserv Flexi Cap Fund - Regular Plan - Growth	10.47 Lac	10.06 Lac (3.95%)
Kotak Manufacture in India Fund - Regular Plan - Growth	8.33 Lac	8.33 Lac no change
Bajaj Finserv Small Cap Fund - Regular Plan - Growth	6.59 Lac	6.48 Lac (1.68%)

Mutual Fund Holder

Jun 26

Shares held

Jul 26

Shares held

Kotak Midcap Fund - Regular Plan - Growth

37.78 Lac

no change

Motilal Oswal Small Cap Fund - Regular Plan - Growth

22.58 Lac

no change

Bajaj Finserv Flexi Cap Fund - Regular Plan - Growth

10.47 Lac

10.06 Lac

(3.95%)

Kotak Manufacture in India Fund - Regular Plan - Growth

8.33 Lac

no change

Bajaj Finserv Small Cap Fund - Regular Plan - Growth

6.59 Lac

6.48 Lac

(1.68%)

Rakesh Kumar

30 Aug • 7:02 PM · SEBI-Registered Analyst

Rubicon Research Limited Results Analysis-Q1FY27

RUBICON

Financial performance and key Operating Metrics (Consolidated) : Operating Revenue for Q1FY27 is Rs. 534 Crs., 51.59% growth YoY, Total Income is Rs. 540 Crs., 52.92% growth YoY, Gross Profit is Rs. 365 Crs., 46.41% growth YoY, EBITDA is Rs. 129 Crs., 61.91% growth YoY, EBITDA Margin is 24.16% improved by 158 basis points YoY, PBT Rs. 110 Crs., 85.31% growth YoY, PAT Rs. 85 Crs. 95.35% growth YoY. On QoQ basis Operating Revenue is up by 3.97%, Total Income is also up by 4.55%, Gross Profit is up by 6.02%, EBITDA is up by 6.43%, PBT is up by 11.84% and PAT is also up by 10.41%. Arinna impact (Q1): acquisition closed, Arinna contribution to consolidated margin is negligible in Q1. Pithampur FDA inspection successfully concluded (procedural 483; subsequent FDA approval on a filing); commercial ramp remains Q1 CY27. US onshore manufacturing entry (NJ) acquired for USD 2.9m, FDA status VAI, commercialization targeted CY27 with specialty/government demand angle and logistics synergies. Management raised FY27 EBITDA margin guidance from 22–23% to 23%. ROCE: 36%, emphasized as strong despite 25% of capital employed tied up in investments that are “pre-revenue or yet to materially contribute.”

Ashish Kumar

26 Aug • 3:42 PM · SEBI-Registered Analyst

Block Deals Spotlight: PhysicsWallah and Rubicon

Shares of PhysicsWallah surged as much as 5% on Wednesday after nearly 4.67 crore shares, representing around 1.6% of the company’s equity, changed hands in multiple block deals valued at approximately Rs 550 crore. The transactions were executed at Rs 117.72 per share, a roughly 3% discount to the previous close of Rs 121. Despite the discounted price, the stock climbed sharply in early trade, touching an intraday high near Rs 127-128. Buyers and sellers in the deals have not been disclosed. As of the end of the June quarter, promoter entities held about 71% stake, with public shareholders owning the remaining 29%. The activity comes amid a strong recovery for the edtech stock, which has risen over 40-60% from its March 2026 low of Rs 77.72. It also follows PhysicsWallah’s Q1 FY27 results, where consolidated revenue grew about 24% year-on-year to Rs 1,054 crore and net loss narrowed significantly. Separately,

RUBICON

esearch saw around 8.4 lakh shares change hands in a block deal worth Rs 140 crore, executed near Rs 1,660 per share. The pharma stock rose as much as 4-6% in response, continuing its strong performance this year. Buyers and sellers in both transactions remain undisclosed. Promoters hold majority stakes in both firms—about 71% in PhysicsWallah and around 60% in Rubicon. These large deals highlight continued investor interest in select mid- and small-cap names amid broader market activity.

Saurabh Tyagi--Clovek,Advisory

20 Aug • 3:53 PM · SEBI-Registered Analyst

RUBICON

announced Q1FY27 results Consolidated Financial Highlights:

RUBICON

announced Q1FY27 results Consolidated Financial Highlights: Revenue from Operations: The company reported revenue of Rs 5,343.38 million in Q1FY27, representing a YoY growth of 51.59% compared to Rs 3,524.94 million in Q1FY26 and a QoQ growth of 3.97% from Rs 5,139.15 million in Q4FY26. Total Income: Total income for Q1FY27 stood at Rs 5,400.21 million, increasing by 52.92% YoY from Rs 3,531.27 million and by 4.55% QoQ from Rs 5,165.25 million. Net Profit after Tax: The company achieved a Net Profit of Rs 847.81 million in Q1FY27, a significant increase of 95.79% YoY from Rs 433.01 million. On a QoQ basis, profit grew by 10.41% from Rs 767.85 million in Q4FY26. Total Comprehensive Income: Total comprehensive income for the quarter was Rs 800.49 million in Q1FY27 compared to Rs 504.18 million in Q1FY26 and Rs 827.39 million in Q4FY26. Earnings Per Share (EPS): Basic EPS grew to Rs 5.13 in Q1FY27 from Rs 2.81 in Q1FY26. Diluted EPS stood at Rs 5.08 compared to Rs 2.79 in the same period last year.

Akhilesh Jat SEBI RA

17 Aug • 9:22 AM · SEBI-Registered Analyst

Rubicon Research Hits Fresh All-Time High on Blockbuster Q1 Show

Rubicon Research [

RUBICON

] rallied up to 9.92% in morning trade, hitting a fresh all-time high of Rs 1,779.70, after posting a strong Q1 FY27 show. Consolidated net profit spiked 95.8% YoY to Rs 84.8 crore from Rs 43.3 crore, while revenue jumped 51.6% YoY to Rs 534.3 crore from Rs 352.5 crore. Profit growth nearly double the pace of revenue growth signals strong operating leverage and margin expansion, a healthy sign for a pharma/specialty business scaling output. The all-time-high breakout reflects strong market conviction in this earnings momentum. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered advisor before making any investment decisions.

SASI KUMAR SEBI RA

26 Jul • 8:50 AM · SEBI-Registered Analyst

While most stocks are still struggling below their highs...

A few are quietly making fresh All-Time Highs. 👀 Large Cap ✓ Bajaj Auto ✓ Titan ✓ Federal Bank Mid & Small Cap ✓ Lloyds Metals & Energy ✓ Laurus Labs ✓ Rubicon Research ✓ Diamond Power Infrastructure ✓ SJS Enterprises Stocks making new ATHs while the broader market remains weak are worth keeping on your watchlist.

Akhilesh Jat SEBI RA

23 Jul • 8:35 AM · SEBI-Registered Analyst

Stocks in Focus: Key Corporate Developments May Drive Attention

HCL Technologies:

HCLTECH

has been chosen by TIM Brasil, the country’s 5G leader, to enable South America’s first cross-platform eSIM transfer capability. The initiative is aimed at simplifying the mobile experience for millions of users in Brazil and marks another milestone in the company’s digital transformation and telecom technology capabilities. Rubicon Research:

RUBICON

has expanded its global manufacturing presence through the acquisition of a manufacturing facility in East Brunswick, New Jersey, from InvaTech Pharma Solutions for an enterprise value of $2.9 million. The transaction provides the company with a strategic manufacturing footprint in the United States. Sona BLW Precision Forgings (

SONACOMS

) : The company has entered into definitive agreements with Japan’s DENSO Corporation to form two joint ventures focused on advanced electric and hybrid powertrain systems, strengthening its presence in the evolving mobility and automotive technology ecosystem. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered advisor before making any investment decisions.

Rubicon Research Ltd. Share Price

Overview

Market Data

Open Price

Prev. Close

Day Low

Day High

52 Week Low

52 Week High

Fundamentals

Quick Bite

Price To Earnings Ratio

Sector PE

PB Ratio

Sector PB

EPS

Dividend Yield

Today's Volume

5 Day Avg. Volume

PEG Ratio

Market Cap.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Mutual Fund Ownership

About Rubicon Research Ltd. 👋

Expert Opinions

News & Events

Frequently Asked Questions

What is the share price of Rubicon Research Ltd.?

What is the market cap of Rubicon Research Ltd.?

Should I buy Rubicon Research Ltd. stock now?

What is the 52 week high and low of Rubicon Research Ltd.?

Is the Rubicon Research Ltd. stock good to buy?

Is Rubicon Research Ltd. a good buy for the long term?

Is Rubicon Research Ltd. overvalued or undervalued?

What is the PE and PB ratio of Rubicon Research Ltd.?